The purpose of this study was to inform the design of randomized clinical trials in early-stage manifest Huntington’s disease through analysis of longitudinal data from TRACK-Huntington’s Disease (TRACK-HD), a multicenter observational study.
We compute sample sizes required for trials with candidate clinical, functional, and imaging outcomes, whose aims are to reduce rates of change.
Background: Placebo effects represent a major drawback in clinical trials, and their magnitude hampers the development of new treatments. Previous research showed that prior exposure to active treatments increases the placebo response for muscle rigidity in Parkinson’s disease.
Methods: We investigated the effects of prior exposure to apomorphine on the placebo response of another cardinal symptom of Parkinson’s disease, bradykinesia, by a movement time analyzer.
Approximately 10% of Parkinson’s disease (PD) patients have young-onset PD (YOPD). From a public health perspective, YOPD is an important subgroup of PD patients, because they are expected to remain active users of the health care system for many decades.
In this age of digital technology, Internet, and social media we are increasingly subjected to an information and disinformation overload. This includes not only political and economic information but also medical news, which is often presented as a “new discovery”, “miracle cure” or some other press hyperbole.